Roche’s Cobas Liat Test for COVID-19 Granted FDA Emergency Use Authorization

The FDA has granted Emergency Use Authorization to Roche’s cobas SARS-CoV-2 nucleic acid test for use on the company’s cobas Liat system.

The point-of-care reverse transcriptase polymerase chain reaction (RT-PCR) test system, which can identify COVID-19 infections in 20 minutes or less during a patient’s visit, offers an alternative to sending test samples to a PCR test laboratory.

Roche says the PCR test will be available for use on the cobas Liat system in July.